ArticleOncology letters2026
Survival benefits of non-surgical triple therapy in hepatocellular carcinoma with inferior vena cava/right atrial tumor thrombus: A retrospective analysis from a multidisciplinary team.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) with inferior vena cava and/or right atrial tumor thrombus (IVC/RA TT) is associated with extremely poor prognosis, and the optimal non-surgical treatment approach remains unclear. The current retrospective cohort study aimed to evaluate the efficacy of multidisciplinary team (MDT)-guided non-surgical management in 41 patients with HCC and IVC/RA TT treated at West China Hospital (Sichuan University, Chengdu, China) between January 2019 and December 2023. Patients were categorized according to treatment modality into the following four groups: Systemic therapy alone (n=8), mono-locoregional therapy (n=4), dual-modality therapy (n=14) and triple-modality therapy consisting of systemic therapy, stereotactic body radiation therapy and transarterial chemoembolization (n=15). The triple-modality group displayed significantly longer median overall survival (15 months) and progression-free survival (7 months) compared with the other treatment groups (P=0.019 and P=0.03, respectively). Multivariable Cox regression analysis identified triple-modality therapy as a significant independent protective factor for survival. In addition, this regimen exhibited a favorable safety profile, with no grade ≥3 treatment-related adverse events observed. These preliminary findings suggest that MDT-guided triple-modality combination therapy represents a feasible, safe, and well-tolerated strategy that might offer survival benefits for this high-risk population, although further large-scale validation is necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.